New Atmosphere, New Vision: Gibson and Whittemore Kick Off Invest in ME Conference 2016
Mark Berry reports on Dr. Gibson's introduction and Dr. Whittemore's keynote speech, at the 11th Invest in ME International ME Conference in London.
Discuss the article on the Forums.

Anti-EBV Drug Under Development at Wistar Institute

Discussion in 'Latest ME/CFS Research' started by Gemini, Jul 13, 2015.

  1. Gemini

    Gemini Senior Member

    Wistar Institute researchers homing in on a novel anti-EBV drug that disables the EBNA1 protein received a three-year $5.6 million grant from the U.K. based Wellcome Trust...

    Targeting EBV related cancers, researchers believe it may also have value for diseases like MS and mono.

    They've met with the FDA to discuss the design of human trials expected to begin in 2018.

    If initial trials succeed they'll look for a pharmaceutical company to underwrite final trials.

    Sounds encouraging...

See more popular forum discussions.

Share This Page